Do you want to read an article? Please log in or register.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1
Genitourinary Cancer
Related content
COMMENTED
Genitourinary Cancer
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Clin Oncol
Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, Herchenhorn D, Zhang T, Beckermann KE, Vapiwala N, Carducci MA, Celano P, Hotte SJ, Basu A, Borno H, Bryce AH, Wang P, Wulff-Burchfield E, Bodei L, Loblaw A, Hamilton RJ, Emamekhoo H, Hope TA, He H, Murad MH, Liu H, Williams JE Jr, Parikh RA
doi: 10.1200/JCO-25-00007
Genitourinary Cancer
Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience
Prostate
Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H
doi: 10.1002/pros.24880
Genitourinary Cancer
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Lancet Oncol
Matsubara N, Azad AA, Agarwal N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, Fizazi K
doi: 10.1016/S1470-2045(25)00030-0
Genitourinary Cancer
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Lancet Oncol
Fay AP, Fizazi K, Matsubara N, Azad AA, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cislo P, Chang J, Healy CG, Niyazov A, Agarwal N
doi: 10.1016/S1470-2045(25)00031-2
Genitourinary Cancer
Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Lancet Oncol
Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, Herrmann K, Roubaud G, Nagarajah J, Fleming M, Lewis B, Nordquist L, Carnahan N, Ghebremariam S, Hertelendi M, Castellano D, Sartor O
doi: 10.1016/S1470-2045(25)00189-5
Genitourinary Cancer
Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis
Prostate
Suzuki K, Hirata J, Okamura Y, Bando Y, Hara T, Terakawa T, Hyodo Y, Chiba K, Teishima J, Miyake H
doi: 10.1002/pros.24889
Genitourinary Cancer
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
Ann Oncol
Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Fleming M, Haas T, Ghebremariam S, Kreisl TN, Rajagopalan S, Sartor O, Morris MJ, PSMAfore Investigators
doi: 10.1016/j.annonc.2025.07.003
Genitourinary Cancer
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
Prostate Cancer Prostatic Dis
Yu EY, Suzuki H, Pieczonka CM, Gotto G, Briganti A, Luz M, Murphy D, Malone R, Hamilton J, Chan JE, Sieber P, Given RW, Hellmis E, Kretz T, Spiegelhalder P, Gómez-Caamaño A, Amela YM, Artignan X, Uemura H, Fujita N, Adorjan P, Ghadessi M, Verholen F, Armstrong AJ
doi: 10.1038/s41391-025-01047-7
Genitourinary Cancer
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Lancet
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K
doi: 10.1016/S0140-6736(25)00684-1